Medical research

Empagliflozin doesn't up risk of bone fractures

(HealthDay)—Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care.


Plasma volume changes may mediate effects of empagliflozin

(HealthDay)—The reduction in risk of cardiovascular (CV) death with empagliflozin is most mediated by changes in hematocrit and hemoglobin, according to research published online Dec. 4 in Diabetes Care.


ADA: Empagliflozin linked to reduction in T2DM nephropathy

(HealthDay)—For patients with type 2 diabetes at high cardiovascular risk, empagliflozin is associated with a reduction in incident or worsening nephropathy, according to a study published online June 14 in the New England ...


Empagliflozin in type 2 diabetes: Added benefit not proven

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. The German Institute for Quality and ...